OBJECTIVE: To evaluate the safety and survival benefit of combined curative resection (CR) of the pancreas and major venous resection in the management of borderline resectable @entity788 . METHODS: In this IRB approved retrospective cohort study, @entity1 who had pancreatic surgery (n=274) between 1998-2012 were reviewed. One hundred and seventy-five @entity1 had malignant causes, of which 119 underwent CR. One hundred and two @entity1 who did not require venous resection/repair (Group-I) were compared with 17 @entity1 who had major vascular involvement (portal-vein/superior-mesenteric-vein) and underwent a vascular resection/repair (Group-II) during the CR. Demographics, operative and follow-up data were reviewed. RESULT: Type of the operations were: standard Whipple (n=53), pylorus-sparing-Whipple (n=41), total pancreatectomy (n=11), and distal pancreatectomy (n=13). In Group-II, @entity1211 was excised and primarily repaired (n=12), or repaired using other veins (n=4) or a synthetic patch (n=1). Group-II had a significantly larger @entity5 size and more perineural invasion and peripancreatic soft tissue involvement (P<0.05). While complication rate, margin status, and duration of stay were not different between the groups, the median-overall-survival was higher for Group-I (15.34 months) than Group-II @entity1 (7.18 months) (P=0.003). CONCLUSION: Pancreatic CR requiring intra-operative venous resection/repair is feasible and safe, but the survival of the @entity1 who have @entity788 with @entity1211 is poor irrespective of a successful venous resection.

Curative Resection of XXXX with Major Venous Resection/Repair is Safe Procedure but Will not Improve Survival.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic adenocarcinoma'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous involvement'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor']
@entity788 :: (MESH:D010190,Disease) :: ['Pancreatic Adenocarcinoma']
